P1024: MYLOX-1: A PHASE II STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR GB2064 (WITH FOCUS ON BONE MARROW COLLAGEN) IN PATIENTS WITH MYELOFIBROSIS

• Claire Harrison,
• John Mascarenhas,
• Daniela Cilloni,
• Richard Schlenk,
• Brian Jacoby,
• Robert J Slack,
• Vassilios Aslanis,
• Bhupinder Singh,
• Bertil Lindmark,
• Srdan Verstovsek,
• Raajit K Rampal

Affiliations

Claire Harrison

1 Guys and St Thomas’ NHS Foundation Trust, Department of Haematology, London, United Kingdom

John Mascarenhas

2 Mount Sinai Hospital, Icahn School of Medicine, New York, United States

Daniela Cilloni

3 University Hospital San Luigi Gonzaga, Turin, Italy

Richard Schlenk

4 Heidelberg University Hospital, Department of Hematology, Oncology and Rheumatology, Heidelberg, Germany

Brian Jacoby

5 Galecto Inc., Copenhagen, Medical Affairs Department, Copenhagen, Denmark

Robert J Slack

6 Galecto Inc., Copenhagen, Pharmacology Department, Copenhagen, Denmark

Vassilios Aslanis

7 Galecto Biotech, Clinical Pharmacology Department, Copenhagen, Denmark

Bhupinder Singh

8 Galecto Inc, Clinical Department, Kuala Lumpur, Malaysia

Bertil Lindmark

9 Galecto Inc., Copenhagen, Clinical Pharmacology Department, Copenhagen, Denmark

Srdan Verstovsek

10 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Raajit K Rampal

11 Memorial Sloan Kettering Cancer Center, Leukemia Service, Department of Medicine, New York, United States